Literature DB >> 9565161

Biochemical characterization of recombinant factor IX.

M Bond1, M Jankowski, H Patel, S Karnik, A Strang, B Xu, J Rouse, S Koza, B Letwin, J Steckert, G Amphlett, H Scoble.   

Abstract

Mature human factor IX is a 55,000-d glycoprotein with a modular domain structure and numerous posttranslational modifications. A recombinant form of human factor IX (rFIX) has been produced from a Chinese hamster ovary cell line that was engineered for high-level protein processing and expression. To ensure that the recombinant molecule contains the requisite structural and functional features of the plasma-derived form, rFIX was subjected to detailed biochemical and biophysical characterization. The laboratory studies showed that the posttranslational modifications and primary, secondary, and tertiary structures of rFIX were similar to those of plasma-derived factor IX (pdFIX). In addition, rFIX displayed a high degree of purity and a product release specification for specific activity that is > or = 200 IU/mg.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9565161

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  14 in total

1.  Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.

Authors:  Alessandra Rocca; Simona Pizzinelli; Emily Oliovecchio; Elena Santagostino; Angiola Rocino; Alfonso Iorio
Journal:  Blood Transfus       Date:  2010-04-30       Impact factor: 3.443

2.  Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Authors:  Henrik Østergaard; Jais R Bjelke; Lene Hansen; Lars Christian Petersen; Anette A Pedersen; Torben Elm; Flemming Møller; Mette B Hermit; Pernille K Holm; Thomas N Krogh; Jørn M Petersen; Mirella Ezban; Brit B Sørensen; Mette D Andersen; Henrik Agersø; Haleh Ahmadian; Kristoffer W Balling; Marie Louise S Christiansen; Karin Knobe; Timothy C Nichols; Søren E Bjørn; Mikael Tranholm
Journal:  Blood       Date:  2011-06-23       Impact factor: 22.113

3.  Mini-review on "A novel one-step purification of mouse factor IX".

Authors:  Sumita Choudhury; William E Plautz; Cosette Zacarias; Rinku Majumder
Journal:  J Rare Dis Res Treat       Date:  2016

4.  Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk.

Authors:  Geun-Cheol Gil; William H Velander; Kevin E Van Cott
Journal:  Glycobiology       Date:  2008-05-02       Impact factor: 4.313

5.  A target-specific approach for the identification of tyrosine-sulfated hemostatic proteins.

Authors:  Tzu-An Liu; Shin Yasuda; Frederick E Williams; Ming-Yih Liu; Masahito Suiko; Yoichi Sakakibara; Yuh-Shyong Yang; Ming-Cheh Liu
Journal:  Anal Biochem       Date:  2009-04-05       Impact factor: 3.365

Review 6.  Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.

Authors:  K E Van Cott; P E Monahan; T C Nichols; W H Velander
Journal:  Haemophilia       Date:  2004-10       Impact factor: 4.287

7.  Coagulation Factor IX for Hemophilia B Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov
Journal:  Acta Naturae       Date:  2012-04       Impact factor: 1.845

8.  Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin.

Authors:  Jianming Liu; Anna Jonebring; Jonas Hagström; Ann-Christin Nyström; Ann Lövgren
Journal:  Protein J       Date:  2014-04       Impact factor: 2.371

Review 9.  Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.

Authors:  Maricel G Miguelino; Jerry S Powell
Journal:  Patient Prefer Adherence       Date:  2014-08-08       Impact factor: 2.711

10.  Recombinant human factor IX produced from transgenic porcine milk.

Authors:  Meng-Hwan Lee; Yin-Shen Lin; Ching-Fu Tu; Chon-Ho Yen
Journal:  Biomed Res Int       Date:  2014-05-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.